2575 — Xuanzhu Biopharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$4.29bn
- HK$3.52bn
- CNY51.77m
Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial
Brief: Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium
China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology
Brief: Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston Oncology
Brief: Xuanzhu Biopharmaceutical Posts Full-Year Revenue Of RMB51.8 Million
Brief: Xuanzhu Biopharmaceutical Says Li Jia Kui Resigns As Executive Director
Brief: Xuanzhu Biopharmaceutical Says NG-350A Granted Fast Track Designation By U.S. FDA
China's Xuanzhu hits fresh high on progress of breast cancer treatment
China's Xuanzhu Biopharmaceutical surges in Hong Kong debut